dismiss

Save the Date - Our next Clean Sweep Live Auction will be on Tuesday, September 26th at 9:30AM EST

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

MRI Homepage

Benefits of foetal MR highlighted at ISUOG congress

Explaining bursts of activity in brains of preterm babies

SelectMDx outperforms PCA3 stratifying men for mpMRI

Common cerebral white matter abnormalities found in children with autistic traits

New study offers high resolution images of heart valves

C4 Imaging announces an additional FDA 510(k) clearance for its positive-signal MRI Marker - Sirius

Medical image analysis software market worth 3.88 billion by 2022

Scientists discover and target brain area in patients with schizophrenia who 'hear voices'

MR Solutions receives second Queen’s Award from Lord-Lieutenant of Surrey

Global medical equipment maintenance market to reach $24.83 billion by 2022

Improving the way we assign prostate cancer treatment

Press releases may be edited for formatting or style
Prostate cancer is the most common cancer among men in Europe. Every year around 5000 men in Norway are diagnosed with the disease.

Many different types of prostate cancer cannot be distinguished yet. Researchers have lacked the diagnostic tools to accurately differentiate the aggressive forms from the less aggressive types.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



Some patients require aggressive treatment of the disease, but this isn't always necessary. The inability to assess the extent of the cancer leads to many people being overtreated and subsequent suffering from unnecessary ailments.

A Trondheim-based research group at the Norwegian University of Science and Technology (NTNU) wants to do something about this. Researcher May-Britt Tessem is heading up the team, which is affiliated with the MR Cancer Group at NTNU's Department of Circulation and Medical Imaging.

The European Research Council, affiliated with the EU, is so impressed with the work of the Tessem Group that Tessem has been awarded a prestigious European Research Council (ERC) Starting Grant for her research on prostate cancer.

Distinguishing high-risk cancer forms

Tessem is conducting basic research on prostate cancer. The research group is working on MR prostate imaging.

The group wants to find clinical diagnostic markers that can help prevent overtreatment with its attendant side effects and reduced quality of life. At the same time, the researchers hope to identify the most high-risk cases.

To this end, Tessem and her colleagues aim to provide information about the molecular signature of each patient.

New technology

In the research project supported by the EU, Tessem is shifting from studying one type of cancer in a cell line to retrieving tissue from prostate cancer patients in major tissue biobanks.

"To do this, we'll be using new and groundbreaking imaging technology, called 'multi-omics technology'," she said .

The new technology enables a three-dimensional overview of the tissue and what it consists of.

The technology will be used on one and the same tissue sample from around 1000 patients. These samples come from high quality biobanks at NTNU and St. Olavs Hospital: MR Biobank, Biobank 1 and MRI-Guided Biopsies.

On the path to a solution

Tessem's group is building on one of its recent discoveries. The group has detected two metabolic biomarkers, which are substances in the body that can be analyzed and that tell us something about the condition of the body.

These two particular biomarkers can reveal information about prostate cancer. The biomarkers appear to determine whether prostate cancer patients are likely to relapse after surgery, so they can be important markers for aggressive prostate cancer.
  Pages: 1 - 2 >>

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED